Hims & Hers Health Inc. (HIMS) Revenue-to-Profit Sankey Flow & SEC XBRL Financials
Hims & Hers Health Inc. (HIMS) receives a Roarable Rating of D (Sell) and flashes a Red SELL / AVOID warning (66/100 RQD Confidence). Our SEC filing scanner spotted paper earnings outpacing real operating cash flow (-17.6% (NI vs OCF)) while unpaid customer invoices grew—a classic sign to step aside until cash flow catches up.
How HIMS Turns Every Dollar of Sales Into Real Bottom-Line Profit
Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory
| Fiscal Year | Revenue | Gross Margin | Op Margin | Net Profit | Free Cash Flow | ROIC % |
|---|---|---|---|---|---|---|
| FY 2025 | $2.35B | 73.8% | 4.5% | $128.4M | $194.4M | 8% |
| FY 2024 | $1.48B | 79.5% | 4.2% | $126.0M | $184.6M | 13.6% |
| FY 2023 | $872.0M | 44% | -3.4% | -$23.5M | $34.2M | -1% |
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring HIMS)
- ✓Live walkthrough of HIMS's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
HIMS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +59.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on HIMS today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for HIMS. Explore sector supply chains on /butterfly.
HIMS Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDHow profitable is Hims & Hers Health Inc. (HIMS)?
In FY 2025 (10-K), HIMS converted $2.3B of revenue into a 73.8% gross margin, 4.5% operating margin, and $194.4M in free cash flow (8.3% FCF margin).